{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination significantly expands the repertoire of tumor-specific peptides presented on MHC-I molecules, making the tumor more visible to the immune system.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "The sensitization effect relies on Type I interferon signaling, which is induced by the intratumoral mRNA delivery and is necessary for the observed benefit.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect, confirming the importance of the mRNA payload and not just the delivery vehicle."
    },
    {
      "claim_id": "C03",
      "claim": "The combination of intratumoral mRNA vaccination and anti-PD-L1 therapy significantly increases anti-tumor efficacy, evidenced by increased CD8+ T-cell infiltration and improved control.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models, indicating the necessity of the combination."
    },
    {
      "claim_id": "C04",
      "claim": "A retrospective analysis suggests that metastatic cancer patients who received prior SARS-CoV-2 mRNA vaccination show improved overall survival when subsequently treated with immune checkpoint inhibitors.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
          "line_ref": "L56"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely and limits the strength of the conclusion."
    }
  ]
}
